FinnCap reaffirmed their corporate rating on shares of Cello Health (LON:CLL) in a report released on Friday, Stock Target Advisor reports.

Separately, Liberum Capital reissued a hold rating on shares of Cello Health in a research report on Thursday, January 16th.

Shares of Cello Health stock opened at GBX 138 ($1.82) on Friday. Cello Health has a 1 year low of GBX 100 ($1.32) and a 1 year high of GBX 150 ($1.97). The company has a debt-to-equity ratio of 4.70, a quick ratio of 1.23 and a current ratio of 1.28. The company has a market capitalization of $146.27 million and a P/E ratio of 22.62. The company’s fifty day moving average is GBX 136.03 and its two-hundred day moving average is GBX 128.65.

About Cello Health

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.

Read More: Gap Down Stocks

Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with's FREE daily email newsletter.